Enanta Pharmaceuticals, Inc.
- ENTA
- NASDAQ
- Biotechnology
- Antiviral Drugs
- Liver Disease Therapies
- Small Molecule Drugs
$11.66
Today +5.05%Quote Oct 19, 2026, 04:59 PM UTC
−11.34%over the last month
Max drawdown −15.8%From 1-month high −15.8%3 months −15.7%
Our viewPro
The call stays with Pro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
About Enanta Pharmaceuticals
Enanta Pharmaceuticals, Inc. is a biotechnology firm dedicated to discovering and advancing small molecule therapies designed to combat a range of viral infections and various liver conditions. Its research and development efforts are primarily focused on addressing pathogens such as respiratory syncytial virus (RSV), SARS-CoV-2, human metapneumovirus (hMPV), and the hepatitis B virus (HBV).
Sector
Healthcare
Industry
Biotechnology
Exchange
NASDAQ
Employees
120
Founded
1995
Market value
$339.6M
Quote Oct 19
Analyst target
$20.00
+71.5% from here
Floor
$11.08
5.0% below price
Resistance
$11.71
0.4% above price
The call stays with Pro
7 locked chapters- What to do with this namePro
- Why nowPro
- Why this stockPro
- Section write-upsPro
- Story timelinePro
- News briefPro
- Ask about ENTAPro
Verdict, why now, and the write-up open with Pro. New accounts get 14 days of Pro free.
Log in — 14 days free